{"id":"W4327676480","doi":"10.1007/s13555-023-00910-6","title":"Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Secukinumab; Medicine; Discontinuation; Ixekizumab; Adalimumab; Psoriasis; Psoriasis Area and Severity Index; Psoriatic arthritis; Ustekinumab; Cohort; Dermatology; Internal medicine; Pediatrics; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002469098,0.0003202126,0.0004931217,0.0002248898,0.0003510121,0.00002958953,0.0003171771,0.0003620099,0.0004066474],"category_scores_gemma":[0.00001559094,0.0001741391,0.00007975085,0.0004490888,0.0003283118,0.000106649,0.00002674272,0.0002534491,0.0004665547],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001474303,"about_ca_system_score_gemma":0.00006764934,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000818535,"about_ca_topic_score_gemma":0.0009613914,"domain_scores_codex":[0.9980422,0.0006317752,0.0002964505,0.0004027212,0.0000568397,0.0005699776],"domain_scores_gemma":[0.9988195,0.0006239052,0.0001046957,0.0003910217,0.00003443391,0.00002645285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01051056,0.0005080045,0.8232662,0.00004443516,0.001674334,0.002260162,0.005215241,0.000005302801,0.002169114,0.001998225,0.002392569,0.1499558],"study_design_scores_gemma":[0.02421175,0.0005677844,0.9513234,0.00004069182,0.0001485718,0.004298326,0.0004932294,0.000006555815,0.005210098,0.0002672312,0.01299322,0.0004391473],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926031,0.004602685,0.00002431204,0.001362065,0.0003872999,0.0005328695,0.00003978268,0.0001137599,0.0003341458],"genre_scores_gemma":[0.9943088,0.003496233,0.000008755855,0.001074274,0.00003797236,0.0002468562,0.0001287461,0.00002539606,0.0006729692],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1495167,"threshold_uncertainty_score":0.7101188,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02286308285646909,"score_gpt":0.2595506901935598,"score_spread":0.2366876073370907,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}